Fairvalue-Calculator Fairvalue-Calculator
EN DE

Neurogene Inc (NGNE) Fair Value & Analysis

Healthcare · US · Market cap $498M

Price$30.86
Fair Value$15.70
Upside-49.1%
Quality95/100
Evidence: Low Range $10.36 – $19.62

Fair value as of: Jun 25, 2026

Analysis

Neurogene Inc (NGNE) currently trades at $30.86, while our model-based Fair Value estimate is $15.70 — implying the stock looks roughly 49.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Neurogene Inc (NGNE) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $15.70 versus a price of $30.86 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NGNE?
Our 21-model fair value for Neurogene Inc is $15.70 (as of Jun 25, 2026), built from audited fundamentals. The current price is $30.86.
What is the quality score of NGNE?
Neurogene Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.